EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1| antiplatelet therapy, ffr, recent cardiology trials

EP 60: The Year 2021 in Review with Dr Sukh Nijjer – Part 1

Average (ratings)

No ratings

•

Your rating

In the last Parallax episode of the year,Dr Ankur Kalra welcomed back Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, to review the most impactful events and advances in cardiology from 2021.

This year we had a number of studies that helped clarify our understanding of the world of antiplatelets: First, Ankur and Sukh discuss the take-home messages from HOST-EXAM, a Korean study presented at ACC 2021. They discuss their clinical experiences within the UK and US setting. Next, Sukh talks about the STOPDAPT-2 ACS study, presented at ESC 2021. Sukh interprets the findings in the light of TWILIGHTand summarises his thoughts on the therapy.

2021 was not a great year for physiology: Sukh shares his take on FLOWER-MI, presented at ACC 2021. He offers a deep dive into the data and highlights both the importance of the findings and the limitations of the study.
Next, they discuss RIPCORD 2 from ESC 2021 and finally, Sukh highlights the findings from the FAME 3 trial.

What is the importance of genotype testing in the world of antiplatelets? What are the considerations for clinicians? Should we stop using FFR? How can we incorporate novel findings to patient care? What are the practical considerations that we should take into account when looking at the physiology trials of 2021?

Stay tuned for Part 2 - heart failure and surgical trials coming in 2022.

Questions and comments can be sent to “podcast@radciffe-group.com” and may be answered by Ankur in the next episode. Guest @SukhNijjer, hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

Read MoreRead Less

Episodes

Up Next

EP 61: The Year 2021 in Review with Dr Sukh Nijjer — Top Trials in Heart Failure and Cardiac Surgery

EP61 • Jan 17, 2022 • 53m 30s

In the second part of Parallax’s review of 2021, Dr Sukh Nijjer, Interventional Cardiologist from Imperial College London, and Dr Ankur Kalra discuss key advances in the field of heart failure and cardiac surgery.

All Episodes

01: Conduction Abnormalities After TAVR/TAVI With Chad Kliger

EP01 • Apr 23, 2020 • 27m 44s

In our first episode, Ankur explains his vision for and inspiration to start ‘Parallax’, and speaks with Chad Kliger from Lenox Hill Hospital in New York about conduction abnormalities after transcatheter aortic valve replacement (TAVR/TAVI), a review article published in US Cardiology Review 13.1 Ankur and Chad look at conduction abnormalities after TAVR/TAVI with a focus on basic conduction system anatomy in relation to the aortic valve, the mechanism, incidence, predisposing factors for occurrence, impact on mortality and finally, proposed treatment algorithms for management. Hosted by @AnkurKalraMD. Produced by @RadcliffeCardiology.

... 5 6 7 8 9 10 11 12 13

... 11 12 13

21: The “Interventional Intensivist” With Ann Gage

EP21 • Apr 23, 2020 • 32m 18s

We can count on our fingertips how many interventional intensivists exist in the US.

In this episode Ankur Kalra, MD meets with Dr Ann Gage, Cleveland Clinic’s first ‘interventional intensivist’. She discusses her unique skill set, what it means to be an interventionalist in the cath lab but also an expert in cardiovascular intensive care and advocates why such a unique skill set and critical care training are required in today’s modern medicine.

Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.

Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

20: The Staging Of Aortic Valve Disease: A Novel Approach With Joao Cavalcante

EP20 • Apr 23, 2020 • 41m 53s

Dr Cavalcante meets with Ankur Kalra, MD to discuss his recent review published in US Cardiology Review 13.2; on a new aortic stenosis staging system that has important implications for clinical outcomes following aortic valve replacements to aid the treatment of aortic stenosis.

Listen to this, as well as an overview on his interesting childhood and his views on the future of cardiac imaging to treat TAVR.

Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

19: Women In Cardiology With Kendra Grubb

EP19 • Apr 23, 2020 • 41m 30s

The first female cardiac surgeon qualified in the 1960’s. Today there are only 4.5% women in cardiology and only 4% in thoracic surgery. Ankur Kalra meets with Dr Kendra Grubb, the first women to be trained at the University of Virginia, US, on cardiothoracic surgery and the 250th board certified women in thoracic surgery.

Her recent post on social media went viral. It was a photo of an all-women surgical team carrying out a complex structural heart procedure. It had over 100,000 views and was seen by people in over 75 different countries. It’s clear from this online reaction, that now is the time for women to be recognised for the work they are doing in medicine.

Listen to this engaging discussion between them on the challenges of being a woman in cardiovascular medicine today.

Submit your question to Ankur via: podcast@radciffe-group.com. Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

18: The Year 2019 In Review With Sukh Nijjer

EP18 • Apr 23, 2020 • 1h 58m 55s

In our final episode of the year, Ankur has an long conversation with Sukh Nijjer from Imperial College London about the most impactful, exciting and controversial clinical trials of 2019. Sukh and Ankur also discuss how these trials might change practice in the future, and how practice patterns and decisions differ between the US and the UK. In light of an emerging trend of shared decision making between physicians of different specialities and patients with a vast amount of information at their fingertips, Sukh and Ankur examine what tools they use to reconcile the growing data from clinical trials.

Trials discussed in detail include those presented at the ACC in New Orleans: PARTNER 3 & Evolut Low Risk on TAVR/TAVI, and SAFARI & COAPT on radial vs femoral access; presented at the ESC in Paris: THEMIS and ISAR-REACT 5 on DAPT post-PCI, DAPA-HF on SGLT2i’s for heart failure, and COMPLETE on PCI of non-culprit lesions in STEMI; presented at TCT in San Francisco: TWILIGHT on DAPT post-PCI, and EXCEL at 5 years on PCI vs CABG in left main CAD; and finally, presented at AHA in Philadelphia: ISCHEMIA on medical vs invasive approaches in ischemic events. Submit your question to Ankur via: podcast@radciffe-group.com.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

17: Rasha Al-Lamee On ORBITA, ISCHEMIA, Coronary Revascularisation & Stable Ischemic Heart Disease

EP17 • Apr 23, 2020 • 38m 2s

Recorded before the American Heart Association (AHA) Scientific Sessions 2019, Ankur is joined by Rasha K Al-Lamee, Interventional Cardiologist at Imperial College Healthcare NHS Trust in London and Study Director of the Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial. Rasha talks about how she got into academia, the significance of her end-of-training PhD, and what led to the genesis of ORBITA.

Ankur and Rasha also discuss the findings and unanswered questions of ORBITA, and how recent research in coronary revascularisation and stable ischemic heart disease has (or has not) changed their clinical practice. Finally, in anticipation of its presentation at AHA 2019, Rasha gives an overview of the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). Submit your question to Ankur via: podcast@radciffe-group.com.

Hosted by @AnkurKalraMD. Produced by @RadcliffeCARDIO.

... 19 20 21 22 23 24 ...

... 20 21 22 ...